Developer docs
API playgroundTry for free, no card

Search company profiles

Commonwealth Diagnostics International

Full company profile

uuid000faot

Namestring
Commonwealth Diagnostics International
Legal namestring
Commonwealth Diagnostics International
Websiteurl
commdx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Commonwealth Diagnostics International (CDI) is a privately held, US-based specialty diagnostics company founded in 2017 that focuses exclusively on functional gastrointestinal (GI) diagnostics through hydrogen and methane breath testing. The company's core product portfolio addresses Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption disorders (fructose, lactose, sucrose), with separate adult (10-tube) and pediatric (6-tube) test kits. Testing is conducted using proprietary gas chromatography (GC) instrumentation paired with a proprietary CO2 correction methodology, and supported by the MyGI Gateway HIPAA-compliant provider portal for ordering, tracking, and result delivery. CDI operates a CLIA-certified laboratory and holds ISO 13485, FDA registration, and CE Mark certifications, with its testing approach endorsed by the North American Consensus and ACG Clinical Guidelines.

CDI operates a hybrid go-to-market that combines a sales-led provider channel with a direct-to-patient motion. Healthcare providers (gastroenterologists, primary care physicians, naturopathic doctors) order kits at no cost through the MyGI Gateway portal or online order forms; CDI bills Medicare, Tricare, and a growing roster of commercial payers (Blue Cross Blue Shield of Massachusetts, CareFirst, Premera, Medica, Regence) on behalf of patients, with a registered cost of $699 per test and a maximum patient out-of-pocket of $299 (CPT Code 91065 x 2 units). Patients can also order tests directly for at-home administration with prepaid return shipping to CDI's laboratory. Strategic partnerships with the American College of Gastroenterology, Rome Foundation, Rupa Health, My Total Health, CliniOps, the University of Michigan, and SAM.gov (VA Community Care Network) extend CDI's distribution into conventional gastroenterology, integrative medicine, clinical research, and government healthcare channels across the US and Canada.

Short descriptiontext

Commonwealth Diagnostics International is a privately held US specialty diagnostics company that provides ISO 13485-certified hydrogen and methane breath testing for SIBO, IMO, and carbohydrate malabsorption disorders, serving gastroenterologists, primary care physicians, naturopathic doctors, and patients through its CLIA-certified laboratory and MyGI Gateway provider portal.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSalem, United States
HQ citystring
Salem
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath testing diagnostics, gastrointestinal diagnostics, SIBO breath testing, methane breath analysis, functional GI testing
Industry1 code
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Functional GI Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Testing Services
TypeSubscription Recurring
Description

CDI generates revenue through providing hydrogen and methane breath test kits and laboratory analysis services. Healthcare providers order kits at no cost, and CDI bills insurance (Medicare, commercial insurance, Tricare) on behalf of patients after tests are completed and returned for analysis. Registered cost is $699 per test with maximum patient out-of-pocket of $299.

commdx.com
2Direct Patient Payment
TypeOne Time License
Description

Patients without insurance coverage or those on Medicaid (CDI does not accept Medicaid) pay directly for tests. CDI offers payment plans and financial hardship programs for qualifying patients.

commdx.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Others
Pricing details1 tier
1Insurance-Covered Testing
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

CDI submits claims to commercial insurance, Medicare, or Tricare on behalf of patients. Insurance may cover some or all of the test. Maximum patient out-of-pocket cost is $299 per breath test for patients who pay promptly per CDI billing policies.

commdx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1MyGI Gateway
Description

Centralized hub for managing breath test data and insights, streamlining provider workflows and enhancing patient care through simplified breath testing data management.

commdx.com
Core offering1 text field

Commonwealth Diagnostics International (CDI) provides non-invasive hydrogen and methane breath testing kits and CLIA-certified laboratory analysis services for diagnosing functional gastrointestinal disorders including Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption (fructose, lactose, sucrose). The offering is delivered through at-home or in-office test administration, a proprietary MyGI Gateway provider portal for ordering and result management, and direct insurance billing to Medicare, Tricare, and commercial payers on behalf of patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1 business day turnaround time for test results
+3 more records
Product overview1 text field

Commonwealth Diagnostics International (CDI) offers a portfolio of non-invasive hydrogen and methane breath testing solutions for functional gastrointestinal diagnostics. The product line includes: the SIBO & IMO 10 Tube Breath Test (adult) available with lactulose or glucose substrates; the pediatric SIBO & IMO 6 Tube Breath Test with lactulose; and three carbohydrate malabsorption tests (Fructose, Lactose, and Sucrose malabsorption, each 6 Tube). All tests are supported by the MyGI Gateway platform, a provider-facing web portal for test ordering, data management, and result tracking. Tests can be administered at-home or in-office and are validated for clinical use in both adult and pediatric populations.

Product and service6 records
1SIBO & IMO Hydrogen and Methane 10 Tube Breath Test (Adult)
CategoryDiagnostic Breath Test
Description

Non-invasive at-home hydrogen and methane breath test for adult patients to diagnose Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO); available with lactulose or glucose substrate and 10-tube collection system.

2SIBO & IMO Hydrogen and Methane 6 Tube Breath Test (Pediatric)
CategoryDiagnostic Breath Test
Description

Clinically validated non-invasive hydrogen and methane breath test specifically designed for pediatric patients to detect SIBO and IMO using a 6-tube lactulose-based collection system.

3Fructose Malabsorption Hydrogen and Methane 6 Tube Breath Test
CategoryDiagnostic Breath Test
Description

Non-invasive diagnostic breath test for identifying fructose malabsorption in adult and pediatric GI patients by measuring hydrogen and methane gas produced by gut bacteria in response to unabsorbed fructose.

4Lactose Malabsorption Hydrogen and Methane 6 Tube Breath Test
CategoryDiagnostic Breath Test
Description

Diagnostic breath test for detecting lactose intolerance and malabsorption in adults and children by measuring hydrogen and methane emissions from gut bacteria reacting to lactose.

5Sucrose Malabsorption Hydrogen and Methane 6 Tube Breath Test
CategoryDiagnostic Breath Test
Description

Non-invasive breath test for diagnosing sucrose malabsorption in adults and children by detecting hydrogen and methane levels produced when sucrose is not properly metabolized.

6MyGI Gateway Provider Portal
CategorySoftware Platform
Description

Centralized HIPAA-compliant web portal for healthcare providers to order breath test kits, track orders, and review patient results; available free to providers and integrated with CDI's diagnostic workflow.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-18
Description

Expanded in-network coverage with Regence across the Pacific Northwest and Intermountain Region, improving patient access to CDI's functional GI diagnostics.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-25
Description

Expanded in-network coverage with Medica, strengthening access to affordable functional GI diagnostics across 12 states.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-15
Description

CDI became an approved vendor on SAM.gov, expanding access to government and veterans healthcare networks through VA Community Care Network participation.

4Premera Blue Cross
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-19
Description

Expanded in-network coverage with Premera Blue Cross, improving access for patients in the Pacific Northwest.

commdx.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-18
Description

CDI now in-network with CareFirst BlueCross BlueShield and CareFirst BlueChoice, expanding patient access in the mid-Atlantic region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-20
Description

Strategic partnership with My Total Health to provide comprehensive functional GI diagnostic solutions. My Total Health partners with the American College of Gastroenterology to provide scientific and clinical education to patients suffering from GI symptoms.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-13
Description

CDI ISO 13485-certified breath tests utilized in Owlstone Medical's study of normal levels of hydrogen sulfide in human subjects.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-08-23
Description

Partnership with Rupa Health to expand access to the naturopathic and integrative medicine community. Enables practitioners to order CDI breath tests through Rupa Health's platform.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

ACG partnership through My Total Health to provide scientific and clinical education to patients. CDI aligns with ACG Clinical Guidelines for SIBO diagnosis and treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-27
Description

Ongoing partnership with Rome Foundation working towards cures for Disorders of Gut-Brain Interaction (DGBI). CDI participates in research and educational initiatives.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-10
Description

CDI announced participation in clinical trial with the University of Michigan for functional GI research.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-01-05
Description

Participation in Blue Cross Blue Shield of Massachusetts provider network for functional GI diagnostic services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers9 records
TypeBroad incumbent
Description

Quest Diagnostics is the largest US clinical laboratory offering thousands of tests across all major therapeutic areas. While functional GI breath testing is not a primary focus, Quest's scale and broad payer relationships make it the dominant incumbent reference lab against which CDI competes for commercial insurance volume.

TypeDirect peer
Description

Doctor's Data is a specialty reference laboratory focused on functional medicine testing, including breath tests for SIBO/IMO and malabsorption. They overlap with CDI's naturopathic and integrative medicine customer segment and compete for provider relationships in the functional GI space.

TypeBroad incumbent
Description

LabCorp is one of the two largest US clinical reference laboratories, offering an expansive specialty and routine diagnostics menu. Like Quest, LabCorp has the infrastructure to expand into functional GI breath testing and competes with CDI for hospital and physician office outreach.

TypeDirect peer
Description

Genova Diagnostics is a leading functional medicine laboratory offering a broad menu including hydrogen/methane breath testing for SIBO and carbohydrate malabsorption. They target the same gastroenterology and integrative medicine providers as CDI and serve as a primary competitor in functional GI diagnostics.

TypeBroad incumbent
Description

Eurofins operates a global network of clinical diagnostics laboratories, including specialty and functional medicine testing in the US. With its CE Mark and international regulatory footprint, Eurofins mirrors CDI's positioning on regulatory depth but at vastly greater scale.

TypeBroad incumbent
Description

ARUP is a large nonprofit reference laboratory affiliated with the University of Utah, providing esoteric and specialty testing services to hospitals and physicians nationwide. ARUP represents the broad specialty reference lab category against which CDI positions for academic and large health system business.

TypeBroad incumbent
Description

Sonic Healthcare is a global medical diagnostics operator with significant US laboratory operations including specialty testing. As a broad incumbent, Sonic could expand into functional GI breath testing given its existing infrastructure and payer contracts.

TypeDirect peer
Description

Quintron manufactures clinical gas chromatographic breath analyzers and supplies instruments used by functional GI testing labs and clinics. They are both a potential technology supplier and an adjacent competitor enabling in-office breath testing services.

TypeDirect peer
Description

Gemelli Biotech offers the Trio Smart breath test for SIBO/IMO/H2S, the most directly comparable functional GI breath testing service to CDI in North America. They compete head-to-head for gastroenterology provider ordering and patient-direct business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Commonwealth Diagnostics International

Functional GI Diagnosticscommdx.com

Commonwealth Diagnostics International is a privately held US specialty diagnostics company that provides ISO 13485-certified hydrogen and methane breath testing for SIBO, IMO, and carbohydrate malabsorption disorders, serving gastroenterologists, primary care physicians, naturopathic doctors, and patients through its CLIA-certified laboratory and MyGI Gateway provider portal.

What Commonwealth Diagnostics International does

Commonwealth Diagnostics International (CDI) is a privately held, US-based specialty diagnostics company founded in 2017 that focuses exclusively on functional gastrointestinal (GI) diagnostics through hydrogen and methane breath testing. The company's core product portfolio addresses Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption disorders (fructose, lactose, sucrose), with separate adult (10-tube) and pediatric (6-tube) test kits. Testing is conducted using proprietary gas chromatography (GC) instrumentation paired with a proprietary CO2 correction methodology, and supported by the MyGI Gateway HIPAA-compliant provider portal for ordering, tracking, and result delivery. CDI operates a CLIA-certified laboratory and holds ISO 13485, FDA registration, and CE Mark certifications, with its testing approach endorsed by the North American Consensus and ACG Clinical Guidelines.

CDI operates a hybrid go-to-market that combines a sales-led provider channel with a direct-to-patient motion. Healthcare providers (gastroenterologists, primary care physicians, naturopathic doctors) order kits at no cost through the MyGI Gateway portal or online order forms; CDI bills Medicare, Tricare, and a growing roster of commercial payers (Blue Cross Blue Shield of Massachusetts, CareFirst, Premera, Medica, Regence) on behalf of patients, with a registered cost of $699 per test and a maximum patient out-of-pocket of $299 (CPT Code 91065 x 2 units). Patients can also order tests directly for at-home administration with prepaid return shipping to CDI's laboratory. Strategic partnerships with the American College of Gastroenterology, Rome Foundation, Rupa Health, My Total Health, CliniOps, the University of Michigan, and SAM.gov (VA Community Care Network) extend CDI's distribution into conventional gastroenterology, integrative medicine, clinical research, and government healthcare channels across the US and Canada.

Commonwealth Diagnostics International firmographics

Firmographics
Name
Commonwealth Diagnostics International
Legal name
Commonwealth Diagnostics International
Website
https://commdx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Commonwealth Diagnostics International is a privately held US specialty diagnostics company that provides ISO 13485-certified hydrogen and methane breath testing for SIBO, IMO, and carbohydrate malabsorption disorders, serving gastroenterologists, primary care physicians, naturopathic doctors, and patients through its CLIA-certified laboratory and MyGI Gateway provider portal.
Ownership category
akta.pro rank

Commonwealth Diagnostics International industry classification

Industry
Product category
Functional GI Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)

Keywords

  • Breath testing diagnostics
  • Gastrointestinal diagnostics
  • SIBO breath testing
  • Methane breath analysis
  • Functional GI testing

Where Commonwealth Diagnostics International is headquartered

Location

Headquarters

HQ city
Salem
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Commonwealth Diagnostics International business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Diagnostic Testing Services: CDI generates revenue through providing hydrogen and methane breath test kits and laboratory analysis services. Healthcare providers order kits at no cost, and CDI bills insurance (Medicare, commercial insurance, Tricare) on behalf of patients after tests are completed and returned for analysis. Registered cost is $699 per test with maximum patient out-of-pocket of $299.
  2. Direct Patient Payment: Patients without insurance coverage or those on Medicaid (CDI does not accept Medicaid) pay directly for tests. CDI offers payment plans and financial hardship programs for qualifying patients.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goInsurance-Covered Testing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Commonwealth Diagnostics International product offering

Product offering

Core offering

Commonwealth Diagnostics International (CDI) provides non-invasive hydrogen and methane breath testing kits and CLIA-certified laboratory analysis services for diagnosing functional gastrointestinal disorders including Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption (fructose, lactose, sucrose). The offering is delivered through at-home or in-office test administration, a proprietary MyGI Gateway provider portal for ordering and result management, and direct insurance billing to Medicare, Tricare, and commercial payers on behalf of patients.

Product overview

Commonwealth Diagnostics International (CDI) offers a portfolio of non-invasive hydrogen and methane breath testing solutions for functional gastrointestinal diagnostics. The product line includes: the SIBO & IMO 10 Tube Breath Test (adult) available with lactulose or glucose substrates; the pediatric SIBO & IMO 6 Tube Breath Test with lactulose; and three carbohydrate malabsorption tests (Fructose, Lactose, and Sucrose malabsorption, each 6 Tube). All tests are supported by the MyGI Gateway platform, a provider-facing web portal for test ordering, data management, and result tracking. Tests can be administered at-home or in-office and are validated for clinical use in both adult and pediatric populations.

Differentiator

Problem solved

Functional benefit

Brands

  • MyGI Gateway: Centralized hub for managing breath test data and insights, streamlining provider workflows and enhancing patient care through simplified breath testing data management.

Products and services

  • SIBO & IMO Hydrogen and Methane 10 Tube Breath Test (Adult) Non-invasive at-home hydrogen and methane breath test for adult patients to diagnose Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO); available with lactulose or glucose substrate and 10-tube collection system.
  • SIBO & IMO Hydrogen and Methane 6 Tube Breath Test (Pediatric) Clinically validated non-invasive hydrogen and methane breath test specifically designed for pediatric patients to detect SIBO and IMO using a 6-tube lactulose-based collection system.
  • Fructose Malabsorption Hydrogen and Methane 6 Tube Breath Test Non-invasive diagnostic breath test for identifying fructose malabsorption in adult and pediatric GI patients by measuring hydrogen and methane gas produced by gut bacteria in response to unabsorbed fructose.
  • Lactose Malabsorption Hydrogen and Methane 6 Tube Breath Test Diagnostic breath test for detecting lactose intolerance and malabsorption in adults and children by measuring hydrogen and methane emissions from gut bacteria reacting to lactose.
  • Sucrose Malabsorption Hydrogen and Methane 6 Tube Breath Test Non-invasive breath test for diagnosing sucrose malabsorption in adults and children by detecting hydrogen and methane levels produced when sucrose is not properly metabolized.
  • MyGI Gateway Provider Portal Centralized HIPAA-compliant web portal for healthcare providers to order breath test kits, track orders, and review patient results; available free to providers and integrated with CDI's diagnostic workflow.

Quantifiable outcome

  • 1 business day turnaround time for test results
  • +3 more outcomes

Companies that use Commonwealth Diagnostics International

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles2 records

Commonwealth Diagnostics International technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Commonwealth Diagnostics International partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, minor and flagship.

  • RegencecoreChannel Partner/ Reseller/ Distributor · 18 March 2025Expanded in-network coverage with Regence across the Pacific Northwest and Intermountain Region, improving patient access to CDI's functional GI diagnostics.
  • MedicacoreChannel Partner/ Reseller/ Distributor · 25 February 2025Expanded in-network coverage with Medica, strengthening access to affordable functional GI diagnostics across 12 states.
  • U.S. Department of Veterans Affairs (VA) Community Care NetworkcoreChannel Partner/ Reseller/ Distributor · 15 October 2024CDI became an approved vendor on SAM.gov, expanding access to government and veterans healthcare networks through VA Community Care Network participation.
  • Premera Blue CrosscoreChannel Partner/ Reseller/ Distributor · 19 September 2024Expanded in-network coverage with Premera Blue Cross, improving access for patients in the Pacific Northwest.
  • CareFirst BlueCross BlueShieldcoreChannel Partner/ Reseller/ Distributor · 18 July 2024CDI now in-network with CareFirst BlueCross BlueShield and CareFirst BlueChoice, expanding patient access in the mid-Atlantic region.
  • My Total HealthcoreStrategic or Co-development Partner · 20 October 2022Strategic partnership with My Total Health to provide comprehensive functional GI diagnostic solutions. My Total Health partners with the American College of Gastroenterology to provide scientific and clinical education to patients suffering from GI symptoms.
  • Owlstone MedicalminorStrategic or Co-development Partner · 13 October 2022CDI ISO 13485-certified breath tests utilized in Owlstone Medical's study of normal levels of hydrogen sulfide in human subjects.
  • Rupa HealthcoreChannel Partner/ Reseller/ Distributor · 23 August 2022Partnership with Rupa Health to expand access to the naturopathic and integrative medicine community. Enables practitioners to order CDI breath tests through Rupa Health's platform.
  • American College of Gastroenterology (ACG)flagshipStrategic or Co-development Partner · 26 October 2021ACG partnership through My Total Health to provide scientific and clinical education to patients. CDI aligns with ACG Clinical Guidelines for SIBO diagnosis and treatment.
  • Rome FoundationcoreStrategic or Co-development Partner · 27 August 2020Ongoing partnership with Rome Foundation working towards cures for Disorders of Gut-Brain Interaction (DGBI). CDI participates in research and educational initiatives.
  • University of MichiganminorStrategic or Co-development Partner · 10 January 2020CDI announced participation in clinical trial with the University of Michigan for functional GI research.
  • Blue Cross Blue Shield of MassachusettscoreChannel Partner/ Reseller/ Distributor · 5 January 2019Participation in Blue Cross Blue Shield of Massachusetts provider network for functional GI diagnostic services.

Scale indicators4 records

Recent moves6 records

Expansion highlights2 records

Commonwealth Diagnostics International competitors and assessment

Company assessment

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is the largest US clinical laboratory offering thousands of tests across all major therapeutic areas. While functional GI breath testing is not a primary focus, Quest's scale and broad payer relationships make it the dominant incumbent reference lab against which CDI competes for commercial insurance volume.
  • Laboratory Corporation of America (LabCorp): LabCorp is one of the two largest US clinical reference laboratories, offering an expansive specialty and routine diagnostics menu. Like Quest, LabCorp has the infrastructure to expand into functional GI breath testing and competes with CDI for hospital and physician office outreach.
  • Eurofins Scientific: Eurofins operates a global network of clinical diagnostics laboratories, including specialty and functional medicine testing in the US. With its CE Mark and international regulatory footprint, Eurofins mirrors CDI's positioning on regulatory depth but at vastly greater scale.
  • ARUP Laboratories: ARUP is a large nonprofit reference laboratory affiliated with the University of Utah, providing esoteric and specialty testing services to hospitals and physicians nationwide. ARUP represents the broad specialty reference lab category against which CDI positions for academic and large health system business.
  • Sonic Healthcare: Sonic Healthcare is a global medical diagnostics operator with significant US laboratory operations including specialty testing. As a broad incumbent, Sonic could expand into functional GI breath testing given its existing infrastructure and payer contracts.

Direct peers

  • Doctor's Data: Doctor's Data is a specialty reference laboratory focused on functional medicine testing, including breath tests for SIBO/IMO and malabsorption. They overlap with CDI's naturopathic and integrative medicine customer segment and compete for provider relationships in the functional GI space.
  • Genova Diagnostics: Genova Diagnostics is a leading functional medicine laboratory offering a broad menu including hydrogen/methane breath testing for SIBO and carbohydrate malabsorption. They target the same gastroenterology and integrative medicine providers as CDI and serve as a primary competitor in functional GI diagnostics.
  • Quintron Instrument Company: Quintron manufactures clinical gas chromatographic breath analyzers and supplies instruments used by functional GI testing labs and clinics. They are both a potential technology supplier and an adjacent competitor enabling in-office breath testing services.
  • Gemelli Biotech: Gemelli Biotech offers the Trio Smart breath test for SIBO/IMO/H2S, the most directly comparable functional GI breath testing service to CDI in North America. They compete head-to-head for gastroenterology provider ordering and patient-direct business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Commonwealth Diagnostics International social profiles

Digital presence

Commonwealth Diagnostics International compliance and trust

Trust signal

Compliance5 records

Commonwealth Diagnostics International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Commonwealth Diagnostics International leadership team

Management profile

Number of profiles

Profiles1 record

Commonwealth Diagnostics International funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Commonwealth Diagnostics International M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Commonwealth Diagnostics International

What does Commonwealth Diagnostics International do?

Commonwealth Diagnostics International (CDI) provides non-invasive hydrogen and methane breath testing kits and CLIA-certified laboratory analysis services for diagnosing functional gastrointestinal disorders including Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption (fructose, lactose, sucrose). The offering is delivered through at-home or in-office test administration, a proprietary MyGI Gateway provider portal for ordering and result management, and direct insurance billing to Medicare, Tricare, and commercial payers on behalf of patients.

Is Commonwealth Diagnostics International a public or private company?

Commonwealth Diagnostics International is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Commonwealth Diagnostics International founded?

Commonwealth Diagnostics International was founded in 2017. It employs 11 to 50 people.

Where is Commonwealth Diagnostics International based?

Commonwealth Diagnostics International is headquartered in Salem, United States, in the North America region.

How does Commonwealth Diagnostics International make money?

Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are direct Patient Payment.

Who are Commonwealth Diagnostics International's main competitors?

Broad incumbents on record are Quest Diagnostics, Laboratory Corporation of America (LabCorp), Eurofins Scientific, ARUP Laboratories and Sonic Healthcare. Direct peers are Doctor's Data, Genova Diagnostics, Quintron Instrument Company and Gemelli Biotech.

Does Commonwealth Diagnostics International have an API?

No public API is recorded for Commonwealth Diagnostics International.

What industry is Commonwealth Diagnostics International in?

Commonwealth Diagnostics International's product category is Functional GI Diagnostics. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals